Cardiovascular & hematological disorders drug targets

Vein Pressure Build-Up in Metabolic Heart Disease and Possible Indirect Effects of Dual Incretin Drugs

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Venous congestion is linked to symptoms and organ dysfunction in heart failure.

  • Obesity-related heart failure with preserved ejection fraction (HFpEF) may involve several contributing factors.
  • Metabolic dysfunction is associated with heightened venous congestion in this condition.
  • Inflammation could play a role in worsening venous congestion.
  • Endothelial damage is linked to exacerbated symptoms and outcomes in heart failure.
  • Sodium retention may further aggravate venous congestion in patients with HFpEF.

Simplified

Related papers

Apr '26
Recent progress in treatments and causes of heart failure with normal pumping strength
cited by 8 papers
systematic review
Jul '26
Incretin-Based Treatments for Obesity-Related Heart Failure With Normal Pumping: Potential Benefits Beyond Blood Sugar Control
journal article
Apr '26
Viewing obesity-related heart failure with preserved pumping as a disease affecting multiple organs: treatments based on hormone signals and imaging measures
top 10% journal
cited by 1 paper
journal article
Aug '26
Incretin-Based Treatments for Obstructive Sleep Apnea Linked to Obesity: Review of Evidence Strength and Possible Mechanisms
top 20% journal
journal article
Jun '26
GLP1 receptor agonists in heart failure with preserved pumping function: effects beyond weight loss
top 30% journal
journal article
Jul '26
Comparing GLP-1 or GLP-1/GIP Drugs with SGLT2 Inhibitors in Patients with Irregular Heartbeat and Preserved Heart Function
top 20% journal
Aug '26
Boosting Metabolism by Adding Dual Incretin Therapy After GLP-1 Treatment Alone Is Not Enough
journal article
May '26
Glucagon-like Peptide-1 Treatment in Obesity-Linked Heart Failure with Normal Pumping: How It Works, Evidence, and Importance
top 20% journal
journal article
Jan '26
How the hormones GIP and GLP-1 relate to metabolism and heart health
top 20% journal
cited by 14 papers
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
5 days ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
1 week ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
2 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
3 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
4 weeks ago7 studies
issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
5 weeks ago7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
6 weeks ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
7 weeks ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
8 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief